Apollomics (APLM) Stock Price, News & Analysis

Company Overview

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Key Stats

• Today's Range: $0.13 to $0.14
• 50-Day Range: $0.11 to $0.23
• 52-Week Range: $0.11 to $4.26
• Volume: 315,495 shs
• Average Volume: 1.63 million shs
• Market Capitalization: $12.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Buy

Apollomics Stock Analysis - MarketRank™

Apollomics scored higher than 59% of companies evaluated by MarketBeat, and ranked 408th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Apollomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Apollomics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Apollomics has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.85% of the float of Apollomics has been sold short.

Short Interest Ratio / Days to Cover

Apollomics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apollomics has recently decreased by 79.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apollomics does not currently pay a dividend.

Dividend Growth

Apollomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.85% of the float of Apollomics has been sold short.

Short Interest Ratio / Days to Cover

Apollomics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apollomics has recently decreased by 79.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.03

News Sentiment

Apollomics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Apollomics this week, compared to 1 article on an average week.

Search Interest

Only 14 people have searched for APLM on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

3 people have added Apollomics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Apollomics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 19.13% of the stock of Apollomics is held by institutions.

APLM Stock Analysis - Frequently Asked Questions

How have APLM shares performed this year?

Apollomics' stock was trading at $0.9650 on January 1st, 2024. Since then, APLM stock has decreased by 86.0% and is now trading at $0.1349.
View the best growth stocks for 2024 here.

Who are Apollomics' major shareholders?

Top institutional shareholders of Apollomics include George Kaiser Family Foundation (0.75%).

How do I buy shares of Apollomics?

Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 9/16/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APLM
• CUSIP: N/A
• CIK: 1944885
• Web: www.apollomicsinc.com
• Phone: 886-2-7713-7952
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.00
• High Stock Price Target: $2.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +1,382.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.25
• Quick Ratio: 2.95

Sales & Book Value

• Annual Sales: $1.22 million
• Price / Sales: 9.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 89,496,000
• Free Float: N/A
• Market Cap: $12.07 million
• Optionable: Not Optionable
• Beta: 1.17